Shooting at Moving and Hidden Targets-Tumour Cell Plasticity and the Notch Signalling Pathway in Head and Neck Squamous Cell Carcinomas

• Published in: Cancers Vol. 13; no. 24; p. 6219
• Main Authors: Kałafut, Joanna, Czerwonka, Arkadiusz, Anameriç, Alinda, Przybyszewska-Podstawka, Alicja, Misiorek, Julia O, Rivero-Müller, Adolfo, Nees, Matthias
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 10.12.2021; MDPI
• Subjects: Cancer; Cell cycle; Cervix; Chemoresistance; Chemotherapy; DNA methylation; Dormancy; Drug resistance; Epigenetics; Fibroblasts; Genes; Head and neck carcinoma; Human papillomavirus; Immune checkpoint inhibitors; Immune system; Immunosuppressive agents; Kinases; Ligands; Lymph nodes; Mammals; Mesenchyme; Metastases; Mutation; Notch protein; PD-1 protein; PD-L1 protein; Plasticity; Precision medicine; Proteins; Review; Signal transduction; Squamous cell carcinoma; Stroma; Therapeutic targets; Transformed cells; Tumor suppressor genes; Tumors; human papillomavirus (HPV); cancer stem cells (CSC); Notch signalling pathway; extracellular matrix (ECM); tumour microenvironment (TME); epithelial-to-mesenchymal transition (EMT); metastasis; HNSCC; angiogenesis; intra-tumour heterogeneity (ITH); tumour cell plasticity; head and neck squamous cell carcinoma
• ISSN: 2072-6694; 2072-6694
• DOI: 10.3390/cancers13246219

Head and Neck Squamous Cell Carcinoma (HNSCC) is often aggressive, with poor response to current therapies in approximately 40-50% of the patients. Current therapies are restricted to operation and irradiation, often combined with a small number of standard-of-care chemotherapeutic drugs, preferentially for advanced tumour patients. Only very recently, newer targeted therapies have entered the clinics, including Cetuximab, which targets the EGF receptor (EGFR), and several immune checkpoint inhibitors targeting the immune receptor PD-1 and its ligand PD-L1. HNSCC tumour tissues are characterized by a high degree of intra-tumour heterogeneity (ITH), and non-genetic alterations that may affect both non-transformed cells, such as cancer-associated fibroblasts (CAFs), and transformed carcinoma cells. This very high degree of heterogeneity likely contributes to acquired drug resistance, tumour dormancy, relapse, and distant or lymph node metastasis. ITH, in turn, is likely promoted by pronounced tumour cell plasticity, which manifests in highly dynamic and reversible phenomena such as of partial or hybrid forms of epithelial-to-mesenchymal transition (EMT), and enhanced tumour stemness. Stemness and tumour cell plasticity are strongly promoted by Notch signalling, which remains poorly understood especially in HNSCC. Here, we aim to elucidate how Notch signal may act both as a tumour suppressor and proto-oncogenic, probably during different stages of tumour cell initiation and progression. Notch signalling also interacts with numerous other signalling pathways, that may also have a decisive impact on tumour cell plasticity, acquired radio/chemoresistance, and metastatic progression of HNSCC. We outline the current stage of research related to Notch signalling, and how this pathway may be intricately interconnected with other, druggable targets and signalling mechanisms in HNSCC.